title: [A case of interstitial pneumonia induced by S-1/irinotecan combination therapy].
abstract: A 67-year-old man with multiple liver metastases of colonic cancer was treated with combination therapy of S-1 and irinotecan (CPT-11): S-1 (120 mg/day) administered orally for 14 consecutive days followed by 14 days rest. CPT-11 (100 mg/m(2)) was given as a 2-hour infusion on day 1 and 15. The patient complained of high fever and subsequent exertional dyspnea in the middle of the second course of S-1/CPT-11 therapy. He was hospitalized with severe hypoxemia. CT scan showed extensive ground glass and consolidative changes in bilateral lungs. Steroid pulse therapy with oxygen therapy remarkably improved his symptoms, and abnormal findings on CT scan also resolved. Drug-induced pneumonia needs to be considered in the differential diagnosis when patients treated with S-1/CPT-11 combination therapy present high fever and dyspnea.
authors.affiliation: Dept. of Hospital Pharmacy, Nagoya Memorial Hospital.
authors.forename: Yukari
authors.initials: Y
authors.lastname: Aoki
authors.forename: Shinobu
authors.initials: S
authors.lastname: Kojima
authors.forename: Takae
authors.initials: T
authors.lastname: Kataoka
authors.forename: Seiji
authors.initials: S
authors.lastname: Nagao
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kayukawa
authors.forename: Fumiko
authors.initials: F
authors.lastname: Mori
authors.forename: Ayako
authors.initials: A
authors.lastname: Masaki
authors.forename: Katsuyasu
authors.initials: K
authors.lastname: Yamada
authors.forename: Masaru
authors.initials: M
authors.lastname: Kawai
authors.forename: Megumi
authors.initials: M
authors.lastname: Kabeya
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hibi
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Furuta
authors.forename: Kenji
authors.initials: K
authors.lastname: Ina
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D004338:Drug Combinations; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D017563:Lung Diseases, Interstitial / Q000000981:diagnostic imaging / Q000473:pathology*; D008297:Male; D010094:Oxonic Acid / Q000009:adverse effects* / Q000627:therapeutic use*; D005641:Tegafur / Q000009:adverse effects* / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin